RDInvesting Provides Investors with Free In-Depth Equity Reports on AGN, FRX, GILD and PFE


Follow this company

Companies Mentioned

NYSE:AGN / NYSE:FRX / NASDAQ:GILD / NYSE:PFE
02/05/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Allergan, Inc. (NYSE: AGN) shares increased 2.16 percent to close at $114.69 a share Tuesday. The stock traded between $113.61 and $115.84 on volume of 2.34 million shares traded. Analysts at Citigroup have recently upgraded the company’s rating to "buy" from "neutral". Shares of Allergan have gained approximately 3.0 percent year-to-date.

Find out more about Allergan including full access to the free equity report at:      
www.RDInvesting.com/AGN

Forest Laboratories, Inc. (NYSE: FRX) shares increased 2.67 percent to close at $66.16 a share Tuesday. The stock traded between $65.27 and $66.46 on volume of 2.02 million shares traded. Analysts at JPMorgan have recently upgraded the company’s rating to "overweight" from "neutral". Shares of Forest Laboratories have gained approximately 10.0 percent year-to-date.

Find out more about Forest Laboratories including full access to the free equity report at:       
www.RDInvesting.com/FRX

Gilead Sciences, Inc. (NASDAQ: GILD) shares increased 4.05 percent to close at $82.02 a share Tuesday. The stock traded between $79.85 and $82.06 on volume of 15.15 million shares traded. Analysts at Robert W. Baird have recently upgraded the company’s rating to "outperform" from "neutral". Shares of Gilead Sciences have gained approximately 9.0 percent year-to-date.

Find out more about Gilead Sciences including full access to the free equity report at:     
www.RDInvesting.com/GILD

Pfizer Inc. (NYSE: PFE) shares increased 2.75 percent to close at $31.44 a share Tuesday. The stock traded between $31.25 and $32.00 on volume of 47.18 million shares traded. Analysts at Jefferies have recently upgraded the company’s rating to "buy" from "hold". Shares of Pfizer have gained approximately 2.5 percent year-to-date.

Find out more about Pfizer including full access to the free equity report at:     
www.RDInvesting.com/PFE

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:                     
Research Driven Investing               
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *